Icotrokinra results show potential to set a new standard of …
SPRING HOUSE, Pa. (March 8, 2025) – Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of …
Protagonist Reports Positive Top Line Results From Phase 2b …
Mar 10, 2025 · The study conducted by Protagonist's collaboration partner, Johnson & Johnson, met its primary endpoint of clinical response a in all icotrokinra dose groups evaluated.
New Phase 3 Data on Icotrokinra Suggest Efficacy for Genital, …
May 9, 2025 · Key Takeaways Icotrokinra, an oral peptide, significantly improved psoriasis symptoms in high-impact areas, achieving clear or almost clear skin in 66% of scalp and 77% …
Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials …
Mar 12, 2025 · Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission. Johnson & Johnson has shared positive results from multiple …
Johnson & Johnson's Icotrokinra Shows Significant Skin …
May 10, 2025 · In a Phase 3 trial, investigational icotrokinra led to 66% of scalp psoriasis patients and 77% of genital psoriasis patients achieving clear or almost clear skin specifically on those …
Icotrokinra Shows High Rates of Skin Clearance in Scalp, Genital ...
May 12, 2025 · The therapy was jointly discovered by Protagonist Therapeutics, Johnson & Johnson, and Janssen Biotech. ICONIC-TOTAL is a multicenter, randomized, double-blind, …
Johnson & Johnson files for FDA approval of oral IL-23 inhibitor …
Aug 6, 2025 · In the ICONIC-ADVANCE 1 and 2 studies, icotrokinra not only met co-primary endpoints (Psoriasis Area and Severity Index response of 90 percent or greater improvement …
Significant Improvement in Psoriasis Seen With Oral Drug
Mar 17, 2025 · ORLANDO, Fla. — Adults with moderate to severe plaque psoriasis taking the novel oral drug icotrokinra had significant improvement starting at week 16, with increased …
Icotrokinra Improves Skin Clearance and Cuts Plaque Psoriasis …
Nov 19, 2024 · Icotrokinra is an investigational oral IL-23 inhibitor peptide. Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe …
Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine …
Apr 14, 2025 · Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists EXTON, PA, April 14, 2025 – Johnson …